Health care stocks were mixed Tuesday afternoon, with the NYSE Health Care Index shedding 0.2% and the State Street Health Care Select Sector SPDR ETF (XLV) fractionally higher.

The iShares Biotechnology ETF (IBB) climbed 1.2%.

In corporate news, BioNTech's (BNTX) co-founders plan to leave the German drugmaker to establish a new independent company focused on messenger ribonucleic acid, or mRNA, technologies, while the firm provided a full-year revenue outlook below market expectations. Its shares dropped 20%.

Novo Nordisk (NVO) said Tuesday it received a warning letter from the US Food and Drug Administration on March 5 related to a Post-marketing Adverse Drug Experience inspection conducted in early 2025 at its Plainsboro, New Jersey site. Novo shares fell 3%.

Capricor Therapeutics (CAPR) shares jumped 10% after it said Tuesday the US Food and Drug Administration has lifted its previously issued Complete Response Letter and resumed review of the biologics license application for Deramiocel, a potential treatment for Duchenne muscular dystrophy cardiomyopathy.